Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Establishing Optimal Parameters for Tissue Engineered Corneal Endothelium
Author Affiliations & Notes
  • Itzel Becerril
    Advanced Therapies in Ophthalmology and Visual Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Judith Zavala
    Advanced Therapies in Ophthalmology and Visual Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Hannia M Macias
    Advanced Therapies in Ophthalmology and Visual Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Carlos A Rodríguez-Barrientos
    Advanced Therapies in Ophthalmology and Visual Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Jorge E Valdez
    Advanced Therapies in Ophthalmology and Visual Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Footnotes
    Commercial Relationships   Itzel Becerril None; Judith Zavala Ocular Biodesign Co., Code O (Owner); Hannia Macias None; Carlos Rodríguez-Barrientos None; Jorge Valdez Ocular Biodesign Co., Code O (Owner)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4485. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Itzel Becerril, Judith Zavala, Hannia M Macias, Carlos A Rodríguez-Barrientos, Jorge E Valdez; Establishing Optimal Parameters for Tissue Engineered Corneal Endothelium. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4485.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Lack of proliferative capacity of corneal endothelial cells (CEC) is associated with loss of corneal transparency, compromising visual acuity. Corneal transplantation is required to restore vision; however, the donor shortage worldwide limits this strategy. Tissue engineering is a promising approach that lacks standardization methods, making the transition from bench to bedside complex. This study aims to set parameters for optimal engineered construct production for endothelium regeneration based on Collagen Vitrigel Membranes (CVM) and CEC. We evaluated i)Biomaterial characterization, ii)Primary cell culture standardization (Rabbit CEC), and iii)Tissue engineering cell proliferation NR (Neutral Red).

Methods : This project was conducted through 3 stages: i) CVM for production, concentration (1x,2x,3x) was tested; transmittance and cell proliferation ii) For procurement of cornea (enucleation vs cornea-scleral ring segment) and RCEC culture expansion (Opti-MEM vs MEM) were evaluated for optimization iii) CMV-CEC engineered corneal endothelium construct; different cell densities (2500, 5000 and 7000 cells/mm2) were seeded in 2x CMV over 5 days. NR assay was performed to evaluate cell growth concentration. Paired and unpaired t-test were performed to evaluate the significant difference between the cell growth concentrations during time.

Results : Described per stages as previously described i) CVM production using 2x shows a transmittance above 95% and better cell adherence and proliferation than 1x and 3x. ii) For RCEC isolation, enucleation is a better method for sample isolation than cornea-scleral ring. Cell circularity is higher cultured with MEM medium than with OptiMEM. Moreover, ~1,100 cells/mm2 is the minimum to guarantee the highest cell density monolayer with a hexagonal pattern. iii) No significant difference has been shown in cell proliferation with and without CVM (p>0.05). Significant differences in cell loss from day 2 to 3 for all cell densities (p= 0.00388, p=0.00404, p= 0.04371); however, middle density shows better cell proliferation behavior.

Conclusions : For optimal tissue engineered corneal endothelium; seeding on 2x CMV 5,000 cells/mm2 with OptiMEM for maximum 2 days to guarantee hexagonal cells above 2,100 cells/mm2. These findings contribute by setting the parameters to produce a standardized construct that could be used for transplantation for future pre-clinical models.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×